These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7022877)

  • 21. Antithymocyte globulin therapy after renal transplantation at the Massachusetts General Hospital.
    Delmonico FL
    Transplant Proc; 1984 Aug; 16(4):979-82. PubMed ID: 6380062
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 23. The high dose therapy of anti-human lymphoblast globulin in living related renal transplantation.
    Dohi K; Fukuda Y; Asahara T; Yahata H; Ono E; Takenaka M; Marubayashi S; Omotehara T; Tabe Y; Eto T
    Hiroshima J Med Sci; 1984 Jun; 33(2):223-31. PubMed ID: 6384144
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunologic monitoring of antithymocyte globulin treatment for acute allograft rejection.
    Delmonico FL; Nelson PW; Colvin RB; Cosimi AB
    Transplant Proc; 1984 Dec; 16(6):1492-3. PubMed ID: 6390852
    [No Abstract]   [Full Text] [Related]  

  • 25. The clinical value of antilymphocyte antibodies.
    Cosimi AB
    Transplant Proc; 1981 Mar; 13(1 Pt 1):462-8. PubMed ID: 7022874
    [No Abstract]   [Full Text] [Related]  

  • 26. Reversal of acute renal allograft rejection with adjunctive AG therapy.
    Filo RS; Smith EJ; Leapman SB
    Transplant Proc; 1981 Mar; 13(1 Pt 1):482-90. PubMed ID: 7022879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human monocyte spreading. An in vitro test for immunosuppressive potency of antihum lymphocyte globulin.
    Silobrcić V; Mazuran R; Dekaris D; Balner H
    Transplantation; 1976 Jan; 21(1):51-6. PubMed ID: 813340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttransplant serum creatinine area under the curve predicts renal allograft outcome.
    Sumrani N; Hong J; Miles A; Markell M; Distant D; Fleishhacker J; Maursky V; Jean-Baptiste F; Sommer B
    Transplant Proc; 1996 Feb; 28(1):356-7. PubMed ID: 8644260
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical value of the rosette inhibition test in renal allotransplantation.
    Cantaluppi A; Tarantino A; Donati D; Ponticelli C
    Transplant Proc; 1979 Mar; 11(1):379-81. PubMed ID: 377660
    [No Abstract]   [Full Text] [Related]  

  • 30. "In vivo" standardization model for defining the dose-response-dependent graft-protective value of antilymphocyte sera.
    Réthy L; Osz E
    Dev Biol Stand; 1974; 27():233-5. PubMed ID: 4618536
    [No Abstract]   [Full Text] [Related]  

  • 31. Pretransplant T cell levels and renal allograft survival.
    Uittenbogaart CH; Robinson BJ; Malekzadeh MH; Pennisi AJ; Ettenger RB; Fine RN
    Proc Eur Dial Transplant Assoc; 1979; 16():449-53. PubMed ID: 398517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Available methods to modify primary graft rejection (author's transl)].
    Prange CH; Kliems G
    Wien Klin Wochenschr; 1977 Jul; 89(14):465-74. PubMed ID: 302531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
    Knight RJ; Kerman RH; Zela S; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2003 Apr; 75(8):1301-6. PubMed ID: 12717220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Improvement of the results of renal transplantation by the use of antilymphocyte globulin (ALG)].
    Renna E; Alfani D; Monari C; Trovati A; Berloco P; Famulari A; Cucchiara G; Cortesini R
    Minerva Chir; 1980 May; 35(10):747-50. PubMed ID: 7005730
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses.
    Cosimi AB; Burton RC; Kung PC; Colvin R; Goldstein G; Lifter J; Rhodes W; Russell PS
    Transplant Proc; 1981 Mar; 13(1 Pt 1):499-503. PubMed ID: 7022882
    [No Abstract]   [Full Text] [Related]  

  • 36. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies for kidney allograft rejection.
    Med Lett Drugs Ther; 1986 Oct; 28(724):97-8. PubMed ID: 3531791
    [No Abstract]   [Full Text] [Related]  

  • 38. Refractory acute renal allograft rejection successfully treated with photopheresis.
    Genberg H; Kumlien G; Shanwell A; Tydén G
    Transplant Proc; 2005 Oct; 37(8):3288-9. PubMed ID: 16298575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study.
    Howard RJ; Condie RM; Sutherland DE; Simmons RL; Najarian JS
    Transplantation; 1977 Dec; 24(6):419-23. PubMed ID: 339438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.